Structure and biological activity of isolates from Anogeissus acuminata. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Structure and biological activity of isolates from Anogeissus acuminata.

Diss Abstr Int [B]; 54(12):6218 1994. Unique Identifier : AIDSLINE ICDB/95607141
Rimando AM; Univ. of Illinois at Chicago, Health Sciences Center


Abstract: Phytochemical work on Anogeissus acuminata [(Roxb ex DC) Guill and Perr var lanceolata Wall ex CB Clarke] (Combretaceae) led to the isolation of three new and four known compounds. The new compounds were identified as 2-(2',4'-dihydroxybenzyl)-3-(3',4' methylenedioxybenzyl)-1,3-butadiene, which was given the common name anolignan A; 2,3-bis-(4-hydroxybenzyl)-1,3-butadiene, which was named anolignan B; and 2,3-cis-3,4-cis-4,5-cis-2,5-bis-(4-hydroxyphenyl)-3,4-dimethyltet- rahydrofuran, which was named 2-epi-larreatricin. The four known compounds isolated were (-)-secoisolariciresinol, dihydrodehydrodiconiferyl alcohol, conocarpan, and pterostilbene. The structures of these compounds, including the stereochemistry of 2-epi-larreatricin, were established by various spectroscopic methods including UV, IR, MS, NMR. Through the use of 2D-NMR experiments, revision of the 1H and [13C]-NMR assignments of dihydrodehydrodiconiferyl alcohol, and of the [13C]-NMR assignments of pterostilbene were made. Through bioactivity-guided fractionation, anolignans A and B were identified as the constituents acting together to inhibit HIV-1 reverse transcriptase activity. Anolignan B, which was weakly active by itself, demonstrated higher activity in combination with anolignan A. The activity of anolignan A was also enhanced in the presence of anolignan B. With the exception of (-)-secoisolariciresinol, all the isolates demonstrated cytotoxicity in vitro. Significant cytotoxicity was shown by anolignan A and pterostilbene against breast cancer cell line and by anolignan B against fibrosarcoma cell line. The isolates obtained from this work were the first lignans, neolignans and stilbene isolated from Anogeissus. Anolignans A and B were the first dibenzylbutadiene lignans isolated from a plant. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD94-14933)
Keywords: Antineoplastic Agents, Phytogenic/*PHARMACOLOGY Breast Neoplasms/PATHOLOGY Butanediols/*CHEMISTRY/PHARMACOLOGY Fibrosarcoma/PATHOLOGY HIV-1/*ENZYMOLOGY Lignin/*CHEMISTRY/PHARMACOLOGY Molecular Structure Plants/*CHEMISTRY RNA-Directed DNA Polymerase/*ANTAGONISTS & INHIB Spectrum Analysis Tumor Cells, Cultured THESISKWDantineoplasticagents,phytogenic/KWDpharmacologybreastneoplasms/pathologybutanediols/KWDchemistry/pharmacologyfibrosarcoma/pathologyhiv-1/KWDenzymologylignin/KWDchemistry/pharmacologymolecularstructureplants/KWDchemistryrna-directeddnapolymerase/KWDantagonists&inhibspectrumanalysistumorcells,culturedthesis
950530
M9551039

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .